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ABSTRACT
Glaucoma is an incurable ocular disease characterized by apoptotic cell death and
degeneration of retinal ganglion cells (RGCs), and is one of the leading causes of blindness
worldwide (Quigley and Broman, 2006; Quigley et al., 1995). While current treatments are
effective at slowing vision loss, glaucoma’s multifactorial etiology has made it difficult for
researchers to identify a target for treatment that will permanently halt RGC degeneration.
Previous studies have proposed a glutamate-induced excitotoxic mechanism of RGC death in
glaucoma, and neuroprotective agents have been investigated to prevent this effect. One agent,
acetylcholine, has been shown to initiate pro-survival signaling cascades by binding to α7
nicotinic acetylcholine receptors (nAChRs) on RGCs, and prevents glutamate excitotoxicity
when applied prior to glutamate insult.
PNU-282987, a drug developed by Pharmacia and Upjohn, is a specific α7 nAChR
agonist that has been shown to prevent RGC death in an in vivo rat model of glaucoma in a dosedependent manner. In this study, immunofluorescent staining techniques were utilized to
investigate the effects of 2mM PNU-282987 on RGC survival when applied as an eye drop for
varying amounts of time before performing a procedure to elicit glaucoma-like conditions in rats.
In addition, experiments investigating the involvement of caspase-3 in the apoptotic mechanism
of the in vivo glaucoma model were conducted. It was determined that 2mM PNU-282987
provided a neuroprotective effect against RGC death when applied to eyes for short periods of
time prior to the onset of glaucoma-like conditions, but also resulted in apoptotic and
proliferative effects when applied for extended periods of time. Additionally, it was found that
caspase-3 was involved in the apoptotic mechanism associated with the in vivo model of
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glaucoma. The results from these studies suggest that PNU-282987 may be a valuable
preventative treatment option for individuals susceptible to glaucoma development.
INTRODUCTION
Eye Anatomy and Physiology
In order to understand the mechanism of retinal damage associated with glaucoma, a
basic understanding of human eye anatomy is required (Figure 1). The whole eye is enclosed by
three separate layers of tissue, and the interior of the eye is divided into an anterior chamber
filled with fluid called aqueous humour, and a posterior chamber filled with fluid called vitreous
humour. The sclera is the most superficial layer of tissue that composes the “white” of the eye,
and consists of a dense collagen fiber network to provide protection and support for the eye’s
internal components (Schwartz, 1999). On the anterior surface of the eye rests a transparent
tissue continuous with the sclera called the cornea. The cornea’s transparency is a result of its
lattice-like organization of collagen fibers and allows photons of light from the environment to
enter the eye (Lens et al., 1999).
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Figure 1
Anatomy of the human eye. (Image adapted from Virtual Medical Centre at
http://www.virtualmedicalcentre.com)
Beneath the sclera is the uvea composed of the choroid, ciliary body, and iris. The
choroid consists of a large vascular network which nourishes the retina, as well as dark melanin
pigmentation to prevent the scattering of photons that are not absorbed by the retina (Durairaj et
al., 2012; Lens et al., 1999). The anterior portion of the choroid forms a specialized structure
called the ciliary body. The ciliary body contains smooth muscle and is attached to the crystalline
lens of the eye through suspensory ligaments. Contraction of this muscle allows the shape of the
lens to be adjusted and focus light entering the eye (Schwartz, 1999). In addition, the ciliary
body continuously produces aqueous humour in the anterior chamber of the eye, which nourishes
the cornea and lens (Records, 1979). The most anterior portion of the uvea is the iris which
surrounds a central opening called the pupil. The iris also contains smooth muscle, and its
contraction allows the size of the pupil to be altered in order to mediate the amount of light
entering the eye (Schwartz, 1999).
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The innermost tissue layer, located at the back of the eye, is the retina. The retina is a
complex ocular tissue consisting of multiple cell layers including photoreceptors (rods and
cones), horizontal cells, bipolar cells, amacrine cells, and retinal ganglion cells (RGCs) (Figure
2). While RGCs are the primary focus of this thesis, all the cells of the retina play a key role in
visual perception. The retina is ultimately responsible for converting photons of light from visual
stimuli into recognizable electrical signals that are sent to the brain through a process called
phototransduction.

Light
Figure 2
Anatomy of the human retina. Photons of light pass through five cellular layers upon coming in
contact with the retina. From anterior to posterior these layers are: retinal ganglion cell layer,
amacrine cell layer, bipolar cell layer, horizontal cell layer, and photoreceptor cell layer
consisting of rods and cones. (Image adapated from WebVision at
http://webvision.med.utah.edu/imageswv/schem)
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The first step of phototransduction occurs as photons of light pass through the retinal
layers and activates the pigment rhodopsin found in photoreceptor cells. Photoactivated
rhodopsin stimulates the GTP-binding protein transducin to activate cGMP phosphodiesterase
enzymes that hydrolyze cGMP found in the cytoplasm of photoreceptor cells (Schwartz, 1999;
Shastry, 1997). This hydrolysis results in a reduction of cGMP concentration, closure of cGMPdependent cation channels, and hyperpolarization of the photoreceptor cell.
During dark conditions with no photoactivated rhodopsin present, photoreceptors are in a
slightly depolarized state and continuously release the neurotransmitter glutamate at their
synapses with bipolar cells (Records, 1979; Schwartz 1999). Upon hyperpolarization, however,
the amount of glutamate they release is reduced leading to a variety of effects on postsynaptic
bipolar cells depending on which receptors they express. OFF-bipolar cells contain ionotropic
glutamate receptors and experience hyperpolarization in response to decreased glutamate
exposure (Hack et al., 1999). Conversely, ON-bipolar cells express metabotropic glutamate
receptors and depolarize when synaptic glutamate levels fall. This depolarization leads to the
generation of an electrical signal that is then transmitted to RGCs (Baylor and Fettiplace, 1976;
Hack et al., 1999; Massey and Miller, 1987).
Bipolar cells transduce their electrical signals to RGCs by releasing glutamate at their
synapses in response to depolarization (Baylor and Fettiplace, 1976; Massey and Miller, 1987).
This glutamate binds primarily to excitatory kainate receptors on RGCs leading to their
depolarization and furthering the transmission of the electrical signal (Massey and Miller, 1987).
RGC axons converge and form the optic nerve which exits through the posterior region of the
eye known as the optic nerve head (Lens et al., 1999). This optic nerve eventually converges in
the brain at the lateral geniculate nucleus (LGN) of the thalamus. The LGN conveys signals from

	
  

	
  

Heinze	
  6	
  

the optic nerve to the visual cortex of the occipital lobe where visual processing occurs and
results in the conscious perception of sight (Zeman, 1998).
In addition to bipolar cells, specialized cholinergic starburst amacrine cells also synapse
with RGCs in the retina. These cells release acetylcholine onto RGCs and are thought to play a
role in the directional selectivity of their signal transmission in response to visual stimuli
movement (Chalupa and Werner, 2004). In this thesis, the neuroprotective effects of an
acetylcholine agonist have been demonstrated in glaucoma-like conditions suggesting another
role for starburst amacrine cells. Further investigation into the pathogenesis of glaucoma may
reveal that interference with the functionality of starburst amacrine cells under glaucomatous
conditions could compromise the neuroprotective effect of naturally occurring acetylcholine in
the retina.
Glaucoma and Excitotoxicity
Individuals with glaucoma slowly lose vision as RGCs degenerate and die. While the
direct cause of RGC loss is not known, elevated intraocular pressure (IOP) is often exhibited in
glaucoma patients. IOP is thought to cause RGC death by introducing excitotoxicity and
mechanical stress, as well as interfering with anterograde and retrograde axoplasmic flow
necessary for survival (Anderson and Hendrickson, 2013; Quigley, 2011). Currently, all
medications available to treat glaucoma aim to reduce IOP levels. However, while reduction of
IOP can slow the rate of RGC degeneration, it is insufficient to completely halt RGC death in
glaucoma once it has begun. In addition, some patients with glaucoma never exhibit elevated
IOP levels to begin with. As a result, researchers have investigated other possible mechanisms of
damage that could be responsible for RGC death.
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It has been found that individuals suffering from glaucoma exhibit increased levels of the
excitatory neurotransmitter glutamate in their vitreous humour leading researchers to investigate
a possible excitotoxic mechanism of RGC death. (Lam et al., 1999; Quigley, 2011).
Excitotoxicity refers to the apoptotic death of neurons that results from overexposure to an
excitatory neurotransmitter leading to their prolonged stimulation. Previous studies have found
that exposure of cultured porcine retinas to 500µM of glutamate for three days lead to a 42 ± 5%
decrease in RGCs (Wehrwein et al., 2004). In addition, it was found that this excitotoxic effect
occurs through the binding of specific NMDA and non-NMDA glutamate receptors present on
RGCs. Under normal conditions, glutamate binds to both types of receptors on the ganglion cell
surface and opens ionotropic channels that allow cations necessary for proper functioning to
enter the cell. Under excitotoxic conditions, however, chronic and excessive exposure to
glutamate leads to the prolonged influx of cations and results in apoptosis. The mechanism
leading to apoptosis in this system involves an excessive influx of calcium that has been shown
to activate a mitogen-activated protein kinase (MAPK) mediated apoptotic signaling cascade
(Asomugha et al., 2010).
MAPK signaling cascades are highly conserved in eukaryotes and regulate a variety of
cellular functions including differentiation, movement, mitotic division, and apoptosis (Schaeffer
and Weber, 1999). Typically, these cascades occur via sequential phosphorylation and activation
of enzymes specific to different cellular pathways starting with the activation of a MAPK kinase
kinase in response to some stimuli (Schaeffer and Weber, 1999; Zarubin and Han, 2005). MAPK
kinase kinase phosphorylates a MAPK kinase enzyme, which then proceeds to activate one of
three classes of MAPKs. Extracellular signal-regulated MAPKs are generally involved in cell
differentiation and growth, while c-Jun N-terminal (JNK) and p38 MAPKs play a role in
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inflammatory responses and apoptosis (Schaeffer and Weber, 1999; Zarubin and Han, 2005). In
both human and rodent glaucomatous retinas, an increase in p38 MAPK signaling has been
observed (Dapper et al., 2013; Levkovitch-Verbin et al., 2007; Tezel et al., 2003). Furthermore,
previous studies investigating glutamate toxicity in cultured porcine retinas found that
phosphorylated p38 MAPK levels increased over twofold after glutamate insult lending evidence
that glutamate-induced RGC apoptosis is mediated by p38 MAPK (Asomugha et al., 2010).
Initiation of p38 MAPK-mediated apoptotic signaling cascades generally leads to the
activation of tumor protein 53 (p53). p53 up-regulates the expression of Bcl-2-associated X
protein (BAX), which then proceeds to associate with the mitochondrial outer membrane and
form a mitochondrial apoptosis-induced channel. This channel allows cytochrome c to be
released from the mitochondrial inner membrane and enter the cytoplasm of the cell (Buytaert et
al., 2006). Once in the cytoplasm, cytochrome c activates caspase-9 enzymes, which in turn
activate caspase-3 enzymes and ultimately leads to apoptosis. Interestingly, while previous
studies have shown increased p38 MAPK levels after glutamate insult to cultured porcine RGCs,
phosphorylated p53 levels did not significantly increase compared to controls (Asomugha et al.,
2010). However, levels of phosphorylated Bcl-2, an anti-apoptotic protein that acts to block
cytochrome c release from the mitochondria, were significantly less than in control retinas. This
suggests that p38 MAPK’s apoptotic effect may act primarily through the down-regulation of
Bcl-2 rather than the direct activation of p53 (Asomugha et al., 2010; De Chaiara et al., 2006).
In this study, caspase-3 activity was analyzed in the in vivo rat model to provide evidence that
apoptosis is associated with the procedure used to induce glaucoma-like conditions.
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Acetylcholine as a Neuroprotective Agent
In response to the proposed excitotoxic mechanism of damage in glaucoma, researchers
have tried to identify neuroprotective agents that could prevent glutamate-induced RGC death
from occurring. In other diseases of the CNS, such as Alzheimer’s disease and Parkinson’s
disease, nicotine has been shown to provide neuroprotection by binding to nicotinic
acetylcholine receptors (nAChR) on neurons, and triggering a cell survival signal transduction
pathway (Bordia et al., 2007; Hejmadi et al., 2003; Shaw et al., 2002). Since nicotine binds to
nAChR’s, previous studies have tested the neuroprotective effects of both nicotine and ACh in
cultured porcine RGCs exposed to glutamate. It was found that when pretreated with 5µM
nicotine or 5µM ACh two hours before glutamate insult, there was no significant loss of RGCs
when compared to controls (Wehrwein et al., 2004). In addition, it was found that this
neuroprotective effect was mediated by the binding of both α4 and α7nAChR subunits found on
porcine RGCs (Thompson et al., 2006, Wehrwein et al., 2004). These findings suggest that ACh
provides neuroprotection against glutamate excitotoxicity in the retina.
The binding of ACh to nAChRs on RGCs opens ligand-gated ion channels allowing
calcium to enter the cell (Burnashev, 1998). Instead of inducing an excitotoxic effect, the
calcium influx through nAChR channels activates a survival pathway. This raised the critical
question of how calcium influx was able to cause two different effects when entering the same
cell. While excessive influx of calcium through the activation of glutamate channels triggers
apoptosis, calcium permeation through nAChR channels triggers cell survival. To address this, a
study conducted by Brandt et al. (2011) measured levels of calcium entering cultured porcine
RGCs when exposed to varying concentrations of ACh, nicotine, and glutamate. It was found
that even at high concentrations, exposure to ACh and nicotine only allowed relatively low levels
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of calcium into the cell compared to the influx of calcium resulting from the activation of
glutamate channels. This is likely due to the desensitization of nAChRs that occurs following
prolonged binding of agonists (Giniatullin et al., 2005; Yamodo et al., 2009). In fact, even when
applied at a concentration of 500µM, nicotine still provided neuroprotection instead of toxicity.
These results suggest that initiation of calcium-induced survival and apoptotic pathways are
dependent upon the amount of calcium entering the cell. A small influx of calcium prior to a
large influx initiates a survival pathway to precondition the cell against a later insult.
In other systems exhibiting ACh-induced neuroprotection, calcium influx resulting from
the binding of α7nAChRs has been shown to activate a phosphatidylinositol 3-kinase (PI3K) →
protein kinase B (AKT) → Bcl-2 survival pathway (Dasari et al., 2008; Kihara et al., 2001;
Jonge and Ulloa, 2007). Previous studies investigating this survival pathway in cultured porcine
RGCs measured phosphorylated AKT and Bcl-2 levels after exposure to acetylcholine. It was
found that when ACh was applied alone or prior to glutamate insult, both AKT and Bcl-2 levels
increased significantly compared to control levels (Asomugha et al., 2010; Brandt et al., 2011). It
was also found that when inhibitors of PI3K enzymes were applied before exposure to ACh,
AKT and Bcl-2 levels were significantly lower than ACh-induced levels (Asomugha et al.,
2010). In addition, p38 MAPK levels significantly decreased in RGCs treated with ACh alone or
prior to glutamate insult when compared to RGCs that were only exposed to high concentrations
of glutamate. These findings suggest that the binding of α7nAChRs on RGCs may provide
neuroprotection in two ways: by activating the PI3K→AKT→Bcl-2 survival pathway, as well as
down-regulating the expression of p38 MAPK that is critical for glutamate-induced
excitotoxicity.
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PNU-282987
PNU-282987 (N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride) is
an α7nAChR agonist developed by Pharmcia and Upjohn that was initially intended for use as a
neuroprotective treatment in individuals with schizophrenia (Bodnar et al., 2005). However, it
was found to be an unviable treatment option due to its inhibition of vital potassium channels in
the heart (Walker et al., 2006). In glaucoma the use of PNU-282987 as an eye drop may be able
to safely provide neuroprotection as long as it stays local to the retina and never reaches the
heart. To investigate this, previous studies in this lab topically applied 100µM, 1mM, and 10mM
concentrations of PNU-282987 to the eyes of Long Evans rats (Mata, 2013). At different time
points following each application the animals were sacrificed, and retinal and cardiac tissues
were isolated and underwent LC/MSMS processing to detect levels of PNU-282987. It was
found that PNU-282987 reached the retina, and that detectable levels were found up to 12 hours
following topical application. In addition, no detectable levels of PNU-282987 were found in
cardiac tissues, thereby eliminating the concern of potassium channel inhibition in the heart.
Because it has been demonstrated that α7nAChRs are present on the surface of rat RGCs,
studies were conducted to investigate the neuroprotective potential of PNU-282987 as an α7
nicotinic agonist using an in vivo rat model of glaucoma (Iwamoto et al., 2013; Mata, 2013). As
in vitro studies demonstrated that ACh and nicotine could provide neuroprotection of RGCs
when applied before glutamate insult, in the in vivo model bi-daily eye drops of PNU-282987
were applied for three days before a procedure was performed to induce glaucoma-like
conditions (Mata, 2013). After the procedure, the bi-daily application of PNU-282987 continued
for one month before sacrificing the animals and quantifying RGCs. PNU-282987-induced
neuroprotection was observed in a dose dependent manner. While 100µM PNU-282987 did not
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prevent significant RGC loss, both 500µM and 1mM concentrations provided significant
neuroprotection when compared to untreated controls (Mata, 2013). Strangely, it was also found
that when a concentration of 2mM or 10mM was applied, there was a 13.5% increase in RGCs.
Overall, these findings suggest that PNU-282987 has a neuroprotective effect against RGC loss
under glaucoma-like conditions induced in rats.
The objectives of this thesis were designed to follow-up on the findings of previous
studies using PNU-282987. Because neuroprotection of RGCs was observed when 1mM PNU282987 was used, and RGC proliferation occurred when 2mM or 10mM PNU-282987 was
applied, multiple studies were conducted to analyze the neuroprotective effects of 2mM PNU282987 when applied as eye drops for varying amounts of time using an in vivo glaucoma model
in Long Evans rats. The goal of these studies was to determine the extent of neuroprotection
conferred following each period of PNU-282987 application, and to analyze when 2mM PNU282987 induces RGC proliferation. Determining the timeline of PNU-282987’s neuroprotective
effects will allow for a better understanding of its impact on RGCs. In addition, since evidence
for a p38 MAPK-mediated apoptotic mechanism of glaucoma was found in previous in vitro
studies using cultured porcine RGCs, studies to analyze changes in retinal caspase-3 levels in
vivo were conducted. Caspase-3 is a downstream enzyme of p38 MAPK that is involved with
apoptosis, and evaluating its activity following the procedure to induce glaucoma-like conditions
will yield a better understanding of the apoptotic mechanism associated with the in vivo model.
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MATERIALS AND METHODS
Animals
Adult male and female Long Evans Rats between 3 and 6 months of age were used as an
in vivo model for glaucoma. Animals were obtained from breeding colonies at Charles Rivers
Labs in Portage, MI, and kept at Western Michigan University’s animal facility until needed. All
animals were cared for following the guidelines of the Institutional Animal Care and Use
Committee of Western Michigan University.
Inducing Glaucoma-Like Conditions
These studies utilized the same procedure to induce glaucoma-like conditions as previous
studies that investigated the neuroprotective capabilities of PNU-282987 in an in vivo rodent
model (Mata, 2013; Morrison et al., 1997). Rats were anesthetized via a 1ml/Kg intraperitoneal
injection of KAX cocktail consisting of 5mL of ketamine (100mg/mL), 2.5mL of xylazine
(20mg/mL), 1mL of acepromazine (10mg/mL), and 0.5mL of sterile water. To ensure proper
anesthetization, the procedure to induce glaucoma-like conditions was not performed until
animals lacked reflex activity caused by a toe or tail pinch.
The procedure to induce glaucoma-like conditions consisted of injecting the episcleral
veins surrounding the iris with a 2M hypertonic saline solution. As the saline drains from the
veins, NaCl salt crystals precipitate out of solution and cause scarring at the trabecular meshwork
of the eye. This scarring results in inadequate aqueous humour drainage from the eye’s anterior
chamber and an increase in IOP (McKinley et al., 2012; Schwartz, 1999). Previous studies have
confirmed that the elevation of IOP following this procedure is sufficient to cause significant
RGC loss (an average of 26% decrease) (Mata, 2013). A glass needle 40µm in diameter was
pulled from a Narishige electrode puller and used to inject the episcleral veins. The glass needle
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was attached to tapered polyethylene tubing (PE-50, Clay Adams, Parsippan, NJ) that was then
inserted into a 23-gauge needle with the tip filed off. The tip of the glass needle was beveled
prior to injection to ensure easy penetration into the episcleral veins. 50µL of sterile 2M saline
solution was then injected into the episcleral veins of the right eye causing them to blanch. The
blanching effect ensured a proper injection. The left eye was left untouched to serve as an
internal control. Antibiotic cream was applied to the right eye following the procedure, and the
rat was placed back into its cage and monitored until it had completely recovered from
anesthesia before being returned to the animal facility.
Application of PNU-282987
To investigate the effects of 2mM PNU-282987 on retinal ganglion cells, it was applied
as eye drops 2 times each day for different periods of time prior to performing the procedure to
induce glaucoma-like conditions. In some studies, PNU-282987 was applied twice a day via eye
drop for 3 days, 1 day and 1 hour prior to NaCl injection into the episcleral veins. In other
studies, 2mM PNU-282987 was applied for three days prior to injection, and then added bi-daily
for 1 week, 2 weeks, and 4 weeks following the procedure. All animals were sacrificed 4 weeks
after the NaCl injection as previous studies have demonstrated that significant loss of RGCs
normally occurred 1 month following the hypertonic injection into the episcleral veins (Iwamoto
et al., 2013). Drops were administered bi-daily because previous LC/MSMS studies have found
detectable levels of PNU-282987 in the retina for up to twelve hours following ocular application
(Mata, 2013).
The eye drops were prepared by dissolving PNU-282987 in dimethyl sulfoxide to make a
stock solution that was then diluted to 2mM using phosphate buffered saline (PBS) to allow it to
diffuse into the retina after reaching the back of the eye. Eye drops were applied to rats using
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plastic pipettes while they remained in their cages. Following application, the rats received
Cheerios® as positive reinforcement.
Isolation of Retinas and Quantification of RGCs
After animals received PNU-282987 treatment for the designated lengths of time they
were euthanized in a carbon dioxide chamber for at least 3 minutes to ensure death. After 3
minutes, animals were examined for the absence of breathing and reflexes to confirm they were
deceased. The left and right eyes were surgically removed and cut circumferentially behind the
iris to separate the eye’s anterior and posterior halves. After removal of the lens and vitreous
humour, the retinas were carefully extracted from the posterior half of the eyecup. Care was
taken to keep the retinas in one piece. Four cuts towards the optic nerve head were made in the
retinas, which allowed them to be flat mounted and pinned to a sylgard dish using cactus needles
with the RGC layer facing upward (Figure 3). Pinned retinas were then fixed in 10% formalin
overnight at 4°C. After fixation, retinas were rinsed three times with PBS. To block nonspecific
binding, the retinas were incubated in 2% bovine serum albumin (BSA) in PBS containing
0.02% saponin for 30 minutes at 25°C before the application of the primary antibody. The
monoclonal primary antibody used for studies investigating the effects of PNU-282987 was
Thy1.1 (mouse anti-rat IgG; BD Biosciences), which is specific against Thy-1 glycoproteins only
found on RGCs in the retina (Barnstable and Drager, 1984). The retinas were incubated in a
1:300 dilution of Thy1.1 in PBS containing 0.02% saponin for 1 week at 4°C in a humidified
chamber. After 1 week, the retinas were rinsed three times with PBS and incubated in a 1:300
dilution of fluorescent secondary antibody Alexa Fluor 595 (goat anti-mouse IgG;
Invitrogen/Molecular Probes) for another week at 4°C to allow for visualization of labeled RGCs
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under a confocal microscope. After incubation was complete, the tissues were rinsed three times
with PBS and mounted onto glass slides with a 50% PBS and 50% glycerol solution.
Retinal images were obtained using the 60x objective lens of a Zeiss confocal
microscope. Previous glaucoma studies found that the most damage to RGCs occur in the
peripheries of the retina, so pictures of RGCs were taken 4mm from the optic nerve head (Mata,
2013). Four pictures were taken per retina in each of four quadrants 4mm from the optic nerve
head to ensure adequate sampling of RGC density (Figure 3). Pictures were taken throughout the
RGC layer in 1µm increments. Thy1.1 labeled RGCs were counted within an 80µm2 frame in
each of the four quadrants for each retina and averaged. RGC counts from experimental retinas
were directly compared to the internal untreated control RGC counts to determine if any
significant change occurred in the number of RGCs. The 80µm2 frame was placed so as to
minimize inclusion of labeled RGC axon tracts which may have obscured RGC cell bodies.
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Figure 3
Image of a flat mounted retina taken with a light microscope. Green boxes represent areas 4mm
from the optic nerve head where cell counts were performed. (Image taken with modified
labeling from Mata, 2013)
Caspase-3 Labeling and Assessment
In other studies, caspase-3 activity was assessed to determine whether there was a change
in caspase-3 activity in RGCs under induced glaucoma-like conditions. The right eyes of four
adult Long Evans rats were subjected to NaCl injection as described previously while leaving the
left eyes untouched to act as an internal control. The animals were euthanized at 1 day, 1 week, 2
weeks, and 4 weeks following the injection procedure, and their retinas were isolated, flat
mounted, and pinned to a sylgard dish. The retinas were fixed in 10% formalin overnight at 4°C
followed by three rinses with PBS. To block nonspecific binding the retinas were incubated in
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2% bovine serum albumin (BSA) in PBS containing 0.02% saponin for 30 minutes at 25°C
before the application of the primary antibody. The primary monoclonal antibody used for
staining was specific against caspase-3 enzymes (rabbit anti-rat IgG; Millipore). The retinas were
incubated in a 1:300 dilution of the primary antibody in PBS containing 0.02% saponin for 1
week at 4°C in a humidified chamber. After one week the retinas were rinsed three times with
PBS followed by incubation in a 1:300 dilution of fluorescent secondary antibody Alexa Fluor
594 (donkey anti-rabbit IgG; Life Technologies) for 1 week to allow for visualization of caspase3 enzymes under the confocal microscope. After incubation was complete, the tissues were
rinsed three times with PBS and mounted onto glass slides with a 50% PBS and 50% glycerol
solution.
Retinal images were obtained with a Zeiss confocal microscope using a 10x objective
lens. Pictures of the RGC layer were taken in 4µm increments 4mm from the optic nerve head,
and in the region surrounding the optic nerve head itself. While the greatest damage to RGCs has
been shown to occur in the peripheries of the retina, pictures around the optic nerve head were
also taken because of this region’s sensitivity to IOP changes (Mata, 2013; Selbach et al., 1999;
Novack et al., 1990). Experimental and control retinal pictures were analyzed for fluorescence
that would indicate a change in caspase-3 activity.
Statistical Analysis
For studies analyzing the effects of PNU-282987, RGC counts in experimental retinas
were compared to RGC counts in internal controls using Student’s T-tests. P-values < 0.05 were
considered statistically significant. All data values are reported with the mean standard error of
the sample-mean (SEM).
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In studies analyzing changes in caspase-3 activity following the procedure to induce
glaucoma, experimental retinas and internal controls were examined and compared for
fluorescence to determine the presence of activated caspase-3 in the RGC layer. 950µm × 950µm
representative images of both retinal peripheries and regions surrounding the optic nerve head
were analyzed. Since it was impossible to determine whether labeled caspase-3 was present
within apoptotic vesicles, cellular debris, or RGC bodies, isolated points of fluorescence in each
image were quantified as caspase-positive units (CPUs) to verify changes in caspase-3 activity.
Because the aim of this study was to qualitatively determine whether caspase-3 was involved in
the apoptotic mechanism associated with the in vivo model, statistical analysis of CPU counts
was not performed.
RESULTS
Effects of PNU-282987 on RGC Levels
To investigate the effects of PNU-282987 on RGC survival, 2mM PNU-282987 was
applied as eye drops for various amounts of time before and after the procedure to induce
glaucoma-like conditions. One month following NaCl injection, the retinas were removed and
processed with antibodies against the glycoprotein Thy-1. It was found that exposure to PNU282987 treatment for different periods of time had different effects on RGC survival. Figures 4A
and 4B are images of retinas taken by Mata (2013) that show the effects of NaCl injection on
RGC survival without any treatment with PNU-282987. Figure 4A demonstrates the left
untreated eye that served as an internal control. Single arrows indicate RGC bodies, and double
arrows indicate RGC axon tracts that run through the retina. Figure 4B demonstrates the effect
on RGCs 1 month after 2M NaCl injection into the episcleral veins. The region displayed in Fig.
4B was obtained from the same rat that produced Fig. 4A and from the same region of the retina.
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The RGC densities in the experimental retinas (4B) appeared dramatically reduced when
compared to untreated internal controls (4A). In addition, the shapes of RGCs in experimental
retinas had a blebbed and uneven appearance that differed from the smooth rounded control
RGCs. Figures 4C and 4D illustrate the effects on RGCs from another rat when a single drop of
2mM PNU-282987 was applied one hour prior to the procedure to induce glaucoma-like
conditions. The RGCs in the experimental retinas (4D) were similar in shape and density to those
in the internal control retinas (4C). The region displayed in Fig. 4D was obtained from the same
rat that produced Fig. 4C and from the same region of the retina. It was evident that 1 drop of
2mM PNU-282987 prior to NaCl injection provided some level of protection against RGC loss.
Similar results occurred if eye drops were applied 1 and 3 days before NaCl injection into
the episcleral veins. Figures 4E and 4F illustrate the effect of 2mM PNU-282987 on RGCs when
applied twice a day for 1 day prior to injection. RGC shape and density in experimental retinas
(4F) appeared similar to RGCs of the internal control retinas (4E). Likewise, RGC shapes and
densities in experimental retinas that were treated with 2mM PNU-282987 for 3 days prior to
injection (4H) were similar to RGC densities observed in the untreated control retinas (4G)
indicating protection against loss of RGCs that is typically associated with the NaCl injections.
Different effects on RGC survival occurred when 2 mM PNU-282987 was applied for
longer periods of time after NaCl injection into the episcleral veins. The images shown in figures
4I and 4J illustrate the effects that 2mM PNU-282987 had on RGC survival when it was applied
for three days prior to NaCl injection and one week post-injection. While the shape of RGCs in
the experimental retinas (4J) was similar to those in control retinas (4I), RGC density was
reduced in experimental retinas. Protection against RGC loss did not appear to occur under these
conditions.
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The images shown in figures 4K and 4L illustrate the effects that 2mM PNU-282987 had
on RGC survival when it was applied for three days prior to NaCl injection and two weeks postinjection. The shapes of RGCs in experimental retinas (4L) appeared similar to RGCs in control
retinas (4K); however, RGC density was now greater in experimental retinas. Likewise, the
shapes of RGCs in experimental retinas treated with 2mM PNU-282987 for 3 days prior to NaCl
injection and 4 weeks post-injection (4N) appeared similar to control RGCs (4M), but their
density had also increased. Protection against RGC loss and potential RGC proliferation was
evident under both of these conditions.
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Figure 4
Grayscale images of RGCs stained with a fluorescent antibody against Thy 1.1. Images shown
in the left columns represent control untreated retinas obtained from the same animal and from
the same location as the right experimental images, 4mm from the ONH. The right experimental
images were obtained after 2mM PNU-282987 was applied for different periods of time before
and after NaCl injection to induce glaucoma-like conditions. All images were taken 1 month
following NaCl injection to the right eye. Frame B depicts RGCs labeled after NaCl injection
with no PNU-282987 treatment taken from previous studies conducted by Mata (2013). Frame D
depicts RGCs labeled after treatment with 1 drop of PNU-282987 before NaCl injection. Frame
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F depicts RGCs labeled after 1 day of treatment with PNU-282987 before NaCl injection. Frame
H depicts RGCs labeled after 3 days of treatment with PNU-282987 before NaCl injection.
Frame J depicts RGCs labeled after 3 days of treatment with PNU-282987 before NaCl injection
followed by 1 week of treatment post-injection. Frame L depicts RGCs labeled after 3 days of
treatment with PNU-282987 before NaCl injection followed by 2 weeks of treatment postinjection. Frame N depicts RGCs labeled after 3 days of treatment with PNU-282987 before
NaCl injection followed by 4 weeks of treatment post-injection. Single arrows indicate labeled
RGC bodies, and double arrows indicate RGC axon tracts running through the retina.
Quantification of the change in RGC survival after different periods of PNU-282987
application is summarized in Figure 5. Retinas analyzed in studies by Mata (2013) four weeks
after the procedure to induce glaucoma-like conditions without any PNU-282987 treatment had
an average of 26% (± 5.2, N=6) RGC loss, and is included in Figure 5 for comparison. Retinas
that were exposed to 1 drop of PNU-282987 prior to NaCl injection showed statistically
significant protection against RGC loss as indicated by an average RGC decrease of 4.2% (± 4.1,
N=3). Likewise, retinas exposed to PNU-282987 1 day prior to NaCl injection, and for 3 days
prior to NaCl injection also exhibited statistically significant protection. 1 day of treatment only
averaged a loss of 6.7% (± 3.2, N=3) RGCs, and 3 days of treatment averaged a loss of 6.3% (±
3.1, N=3) RGCs. However, this neuroprotective effect changed when 2mM PNU-282987 was
applied for longer periods of time. Retinas exposed to 3 days of PNU-282987 treatment prior to
the NaCl injection and for an additional week post-injection demonstrated significant RGC loss
of 18.3% (±.05, N=3). If PNU-282987 was applied longer than 1 week after the NaCl injection,
proliferation of cells occurred. Significant proliferation of RGCs was observed in retinas that
were treated with PNU-282987 for 3 days prior to the NaCl injection followed by 2 weeks and 4
weeks of subsequent treatment. Retinas treated for 2 weeks following injection averaged a RGC
gain of 28.9% (±10.2, N=3), and retinas treated for 4 weeks following injection had an average
RGC gain of 24.2% (± 2.3, N=3). Overall, statistically significant protection against RGC loss
was only observed when short periods of exposure to 2mM PNU-282987 occurred before the
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procedure to induce glaucoma-like conditions was performed. Prolonged post-procedural
treatment with PNU-282987 appeared to result in the initial death of RGCs, which was then
followed by a period of proliferation.
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Figure 5
Summary of the results following bi-daily eye drop application of 2mM PNU-282987 for
varying amounts of time. Each bar represents the average percent change in the number of RGCs
when compared to untreated internal control conditions 1 month following the NaCl injection
procedure to induce glaucoma-like conditions. Data for 1 drop (N=3), 1 day (N=3), and 3 days
(N=3) of PNU-282987 application prior to injection is included, as well as data from 3 days of
PNU-282987 application prior to injection followed by 1 week (N=3), 2 weeks (N=3), and 4
weeks (N=3) of subsequent application following injection. Error bars represent SEM. Because
the SEM for 1 week of post-injection PNU-282987 treatment was only ±0.05, the error bar does
not expand beyond the data bar’s boundary. *represents data taken from Mata (2013) when eyes
were subjected to the procedure to induce glaucoma-like conditions without any PNU-282987
treatment (N=6) and is included for comparison.
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Changes in RGC Caspase-3 Activity Following NaCl Injection
To investigate the involvement of caspase-3 in the apoptotic mechanism associated with
an in vivo rat model of glaucoma, retinas of left control eyes and right eyes subjected to NaCl
injection were isolated at 1 day, 1 week, 2 weeks, and 4 weeks following the procedure to induce
glaucoma-like conditions. Retinas were subsequently stained, and the peripheral and optic nerve
head regions were analyzed for fluorescence. Because consistent levels of fluorescence were
observed throughout these regions in each retina, a 950µm × 950µm representative image was
taken of each periphery and optic nerve head, and isolated points of fluorescence were quantified
as caspase-positive units (CPUs) to verify changes in caspase-3 activity. The most dramatic
change in caspase-3 activity occurred 1 day following NaCl injection (Figure 6). In the
peripheral region of the control retina there were 111 CPUs (6A), while the experimental retina
exhibited 492 CPUs (6B). Additionally, only 11 CPUs were observed in the region surrounding
the optic nerve head of the control retina (6C), while 175 CPUs were counted in the experimental
retina. This indicates a large increase in caspase-3 activity throughout the retina 1 day following
the procedure to elicit glaucoma-like conditions.
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FIGURE 6
Images of retinas labeled with a fluorescent antibody against caspase-3 taken 1 day after NaCl
injection was performed to induce glaucoma-like conditions. All images were taken from the
same animal. Images in the left column came from the left eye that served as an internal control.
Images in the right column came from the right eye that was subjected to NaCl injection. Frames
A and B depict images taken of the peripheral region of the retina 4mm from the optic nerve
head. Frames C and D depict images taken of the area directly surrounding the optic nerve head.
Single arrows indicate caspase positive units.
Significant changes in caspase-3 activity in retinal peripheries were absent in retinas
analyzed 1 week, 2 weeks, and 4 weeks following the NaCl injection procedure to induce
glaucoma-like conditions. Figure 7 portrays pictures of these retina peripheries, and also includes
the pictures of retinas analyzed 1 day post-injection already depicted in Figure 6 for comparison
(7A,7B). In peripheral images taken of retinas isolated 1 week following the injection procedure
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there were 102 CPUs present in the control tissue (7C) and 114 CPUs present in the experimental
tissue (7D), which did not indicate a significant change in caspase-3 levels under these
conditions. Likewise, CPU counts in the peripheral regions of retinas isolated 2 and 4 weeks
following injection did not differ significantly from controls. In retinas isolated 2 weeks
following NaCl injection the control tissue exhibited 5 CPUs (7E) and the experimental tissue
exhibited 6 CPUs (7F). In retinas isolated 4 weeks after NaCl injection the control tissue only
exhibited 4 CPUs (7G) and the experimental tissue exhibited 3 CPUs (7H). In summary, no
significant change in caspase-3 activity appeared to occur in the retinal peripheries at 1 week, 2
weeks, or 4 weeks following NaCl injection.
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Figure 7
Images of retinas labeled with a fluorescent antibody against caspase-3 taken in the peripheral
regions 4mm from the optic nerve head at different times after NaCl injection to induce
glaucoma-like conditions. Images in rows were taken from the eyes of the same animal. Images
in the left column came from left eyes that served as internal controls. Images in the right column
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came from right eyes that were subjected to the injection procedure to induce glaucoma-like
conditions. Frames A and B depict the images already presented in Figures 6A and 6B of retinas
labeled 1 day after NaCl injection. Frames C and D depict images of retinas labeled 1 week after
NaCl injection. Frames E and F depict images of retinas labeled 2 weeks after NaCl injection.
Frames G and H depict images of retinas labeled 4 weeks after NaCl injection.
Figure 8 depicts the regions surrounding the optic nerve head in both experimental and
control retinas, and also includes pictures of the retinas analyzed 1 day post-NaCl injection that
were in Figure 6 for comparison (8A,8B). The experimental retina isolated 1 week following
injection exhibited 142 CPUs (8D) while the control retina only exhibited 7 CPUs (8C). This
indicates that a significant increase in caspase-3 activity is present at the optic nerve head for at
least a week following the procedure to induce glaucoma-like conditions. However, experimental
retinas isolated 2 weeks and 4 weeks following NaCl injection did not exhibit a significant
increase in CPUs when compared to internal controls. In retinas isolated two weeks following
NaCl injection experimental tissue only exhibited 4 CPUs (8F), and the control tissue exhibited 3
CPUs (8E). In retinas isolated four weeks after NaCl injection the experimental tissue exhibited
4 CPUs (8H), and the control tissue also exhibited 4 CPUs (8G). While caspase-3 activity
appeared dramatically increased at the optic nerve head 1 week post-NaCl injection, no
significant change in caspase-3 activity occurred at 2 weeks or 4 weeks following injection.
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Figure 8
Images of retinas labeled with a fluorescent antibody against caspase-3 taken at the region
directly surrounding the optic nerve head at different times after NaCl injection to induce
glaucoma-like conditions. Images in rows were taken from the eyes of the same animal. Images
in the left column came from left eyes that served as internal controls. Images in the right column
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came from right eyes that were subjected to the injection procedure. Frames A and B depict the
images already presented in Figures 6C and 6D of retinas labeled 1 day after NaCl injection.
Frames C and D depict images of retinas labeled 1 week after NaCl injection. Frames E and F
depict images of retinas labeled 2 weeks after NaCl injection. Frames G and H depict images of
retinas labeled 4 weeks after NaCl injection.
DISCUSSION
Effects of PNU-282987
In this study the neuroprotective effects of 2mM PNU-282987 against RGC death were
investigated when it was applied bi-daily as an eye drop for varying amounts of time using an in
vivo rat model of glaucoma. There was not statistically significant RGC loss when eyes were
pretreated with PNU-282987 for 3 days and 1 day before performing the NaCl injection to
induce glaucoma-like conditions. Likewise, a single drop of PNU-282987 applied one hour
before injection was sufficient to prevent significant RGC death. Significant RGC loss did occur
when it was applied for 3 days prior to the injection procedure and for 1 week following
injection. Under these conditions there was an average RGC loss of 18.3%. Oddly, when PNU282987 was applied for 2 weeks and 4 weeks following NaCl injection dramatic RGC
proliferation was observed. 2 weeks of application led to a 28.9% increase in RGCs, and 4 weeks
of application resulted in a 24.2% increase. While short exposure of PNU-282987’s provided
neuroprotection against the loss of RGCs associated with the NaCl injection, prolonged use
appeared to have a severe effect on cell survivorship.
Studies have shown that the binding of nicotinic agonists to nAChRs allows calcium to
enter the cell, and that prolonged binding desensitizes the receptors and doesn’t allow the influx
of calcium to reach toxic levels (Brandt et al., 2011; Giniatullin et al., 2005; Yamodo et al.,
2009). However, the binding of PNU-282987 to nAChRs for a week appears to be causing cell
death. This apoptosis could be occurring due to greater levels of calcium entering RGCs when
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PNU-282987 binds to nAChRs than when other nicotinic agonists bind resulting in cell death.
Alternatively, RGC death may be due to other mechanisms such as changes in calcium tolerance
that may result from a relatively high concentration of PNU-282987 exposure.
The proliferative effect of PNU-282987 observed after 2 weeks and 4 weeks of
application is strange in that it appears to follow a period of cell death. This effect was
unexpected as adult mammalian retinal neurons do not normally undergo mitotic division. While
the mechanism surrounding this switch from apoptotic to proliferative cell signaling is unknown,
prolonged binding of nAChRs on various non-neuronal cells such as pulmonary endothelium,
keratinocytes, and esophageal epithelium has been shown to induce mitogenic division and lead
to cancer (Egleton et al., 2008; Grando et al., 1996; Jensen et al., 2012). The nicotinic receptor
mediated initiation of cell replication has been shown to occur in a variety of ways, one of which
is the activation of a class of MAPKs known as external signal-regulated kinases (ERKs)
(Egleton et al., 2008; Schaeffer and Weber, 1999). ERKs are involved in a variety of functions
related to cell survival, differentiation, and division. Activation of ERKs occurs in response to
prolonged calcium influx, and initiates a signaling cascade that leads to the transcription of genes
and expression of proteins necessary for cells to enter S phase and prepare for mitosis (Harding
et al., 2003; Schaeffer and Weber, 1999). Normally, RGCs are arrested in Go phase and have
ERKs that mediate survival functions in the cell such as preventing hypoxia-induced apoptosis
and aiding in axonal regeneration (Park et al., 2004; Zhou et al., 2005; Zhou et al., 2007).
However, perhaps the continuous influx of subtoxic levels of calcium that results from prolonged
exposure to PNU-282987 is sufficient to activate ERK-mediated cell replication pathways that
can push RGCs into S phase and lead to mitotic division.
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Caspase-3 Activity
In addition to investigating the neuroprotective effects of PNU-282987, this study also
analyzed the involvement of caspase-3 in the apoptotic mechanism associated with an in vivo rat
model of glaucoma. Fluorescent immunocytochemical techniques were utilized to visualize
caspase-3 enzymes present in RGCs at different time points following the procedure to induce
glaucoma-like conditions. A large increase in caspase-3 activity was observed in the peripheries
and in the regions surrounding the optic nerve head at 1 day following NaCl injection. At 1 week
post-injection, caspase-3 activity did not appear to differ significantly from controls in retinal
peripheries, but there was still an increase in activity around the optic nerve head. By 2 weeks
and 4 weeks after NaCl injection, however, caspase-3 activity did not significantly differ from
controls in the retinal peripheries or around the optic nerve head. These findings support that
caspase-3 is involved in the mechanism of RGC death observed in the in vivo glaucoma model.
In addition, because caspase-3 is a downstream target of the proposed p38 MAPK-mediated
mechanism of apoptosis observed in in vitro studies analyzing glutamate excitotoxicity, these
findings provide evidence that this same apoptotic mechanism may be involved in the in vivo
model (Asomugha et al., 2010).
The most prominent increase in caspase-3 activity observed at just 1 day following NaCl
injection is most likely due to the nature of the injection procedure itself. When NaCl crystals
from the injected saline solution precipitate and drain from the eye, they pass through the
trabecular meshwork causing substantial damage and scarring (Morrison et al., 1997; Mata,
2013). This immediately impedes the outflow of aqueous humour from the anterior chamber, and
IOP levels quickly begin to rise. While this increase in IOP simulates glaucomatous conditions,
its rapid onset does not reflect the process of slow IOP elevation that occurs in patients with
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glaucoma (Quigley, 2011). The significant increase in caspase-3 activity observed 1 day after
NaCl injections may be due to a sudden sharp elevation of IOP, which immediately introduces
profound cellular stress and triggers apoptotic signaling.
Future Studies and Implications
Because application of 2mM PNU-282987 had a variety of effects on RGCs depending
on how long eyes were exposed to it, future studies will need to analyze what specific signaling
pathways PNU-282987 is initiating. Since neuroprotection was observed when it was only
applied prior to NaCl injection into the episcleral veins, analyses of PI3/AKT levels following
2mM PNU-282987 application will need to be performed to determine if the PI3-AKT-Bcl-2
survival pathway proposed by previous studies is a plausible mechanism of protection in the in
vivo rat model of glaucoma (Asomugha et al., 2010; Brandt et al., 2011). In addition, studies
investigating how long the neuroprotective effect of PNU-282987 lasts when applied prior to
NaCl injection need to be conducted. While protection was observed at four weeks following the
procedure to induce glaucoma-like conditions, analysis of RGC survival at 5 weeks, 6 weeks,
etc. post-procedure should be performed. This will provide a time frame for PNU-282987’s
efficacy, and may be able to prevent some of the adverse effects on RGC survival observed when
exposed to the drug for extended periods of time.
To address the apoptotic and proliferative effects that prolonged exposure to 2mM PNU282987 had on RGCs following NaCl injection, this study should be repeated and the levels of
pro-apoptotic and mitogenic enzymes should be analyzed at each time point. Investigating the
fluctuating levels of enzymes like p38 MAPK and ERK in RGCs subjected to different periods
of PNU-282987 exposure will allow for a better understanding of this drug’s action when bound
to nAChR’s. Specifically, the enzyme levels associated with exposure to 2mM PNU-282987 for
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7-14 days should be investigated to determine how RGCs are switching from apoptotic activity
to proliferation.
Because adult mammalian RGCs are not supposed to undergo mitotic division, the RGC
proliferation induced by prolonged exposure to high concentrations of PNU-282987 is puzzling.
The physiology of the RGCs involved needs to be investigated. The key question to address is
whether newly formed RGCs are able to successfully participate in the transmission of electrical
signals generated during phototransduction. If so, could the induction of RGC proliferation under
glaucomatous conditions lead to the restoration of sight in individuals? Studies need to be
conducted to determine whether newly developed RGCs are successfully synapsing with bipolar
and starburst amacrine cells in the retina since these play key roles in electrical signal
transmission. In addition, studies looking at the axonal development of new RGCs need to be
performed to determine whether they are successfully extending to the lateral geniculate nucleus
of the brain. Even if new RGCs are developing correctly, behavioral studies will have to be
performed to determine whether a noticeable improvement in sight is actually occurring as a
result of their induced proliferation. If the controlled induction of functional RGC proliferation
under glaucomatous conditions is perfected, it could have huge implications in current glaucoma
research and treatments. Rather than simply controlling RGC loss, this discovery could reverse
glaucomatous damage and potentially lead to the restoration of sight in patients.
In addition to further characterizing the effects of PNU-282987, this study confirmed that
caspase-3 is involved in the apoptotic mechanism associated with an in vivo rat glaucoma model.
However, further studies need to be conducted to determine what upstream components are
responsible for the activation of caspase-3. Since glutamate is highly suspected to be involved in
RGC death, levels of apoptotic enzymes associated with glutamate excitotoxicity as determined
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by past studies such as p38 MAPK and BAX should be investigated. This will provide a better
understanding of how RGC apoptosis is occurring in the in vivo model, as well as provide more
insight into the neuroprotective mechanism of PNU-282987. Additionally, double labeling
experiments should be conducted to label both caspase-3 enzymes and RGC membranes in order
to determine the specific location of activated caspase-3 following the procedure to induce
glaucoma-like conditions. Distinguishing whether caspase-3 is more prominent within RGCs,
apoptotic vesicles, or cellular debris will provide a more thorough understanding of the process
and rate of apoptosis occurring in vivo.
The results of this study provide evidence for the effectiveness of PNU-282987 as a
potential neuroprotective agent against RGC death in glaucoma. However, because apoptotic and
proliferative effects were also observed at 2mM concentrations, it needs to be further
investigated. It is important to note that previous studies have found that the application of lower
concentrations of PNU-282987 between 500µM-1mM provided only neuroprotection when
applied prior to the onset of glaucomatous conditions without any noticeable adverse effects to
RGCs (Mata, 2013; Iwamoto et al., 2013). Perhaps these lower concentrations could be
developed as a drug that, when used in conjunction with current treatments to lower IOP levels,
may serve as a preventative treatment option for those at risk for developing glaucoma due to age
or genetic predisposition. In addition, if the proliferative effect observed when RGCs are
exposed to high concentrations of PNU-282987 is further characterized, it has the potential to
become a groundbreaking treatment option that could reverse glaucomatous damage.
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